Puzzling questions on antithrombin: Diagnostic limitations and real incidence in venous and arterial thrombosis

Thrombosis Research

Volumn 135, Issue 6, 2015, Pages 1047-1048

  Corral, Javier ^a   Vicente, Vicente ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; HEPARIN; PROTEIN C; PROTEIN S; PROTEINASE; THROMBIN; ANTITHROMBIN III;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY THROMBOSIS; CRYSTAL STRUCTURE; EDITORIAL; GENETIC ANALYSIS; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS; ANTITHROMBIN III DEFICIENCY; CHEMISTRY; FEMALE; GENETICS; MALE;

ANTITHROMBIN III; ANTITHROMBIN III DEFICIENCY; ANTITHROMBINS; FEMALE; HEPARIN; HUMANS; MALE; THROMBOPHILIA;

EID: 84929504869     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.04.012     Document Type: Editorial

References (19)

1. B. Dahlbäck Advances in understanding pathogenic mechanisms of thrombophilic disorders Blood 112 2008 19 27
2. W.M. Lijfering, J.L. Brouwer, N.J. Veeger, I. Bank, M. Coppens, and S. Middeldorp Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives Blood 113 2009 5314 5322
3. B.K. Mahmoodi, J.L. Brouwer, M.K. Ten Kate, W.M. Lijfering, N.J. Veeger, and A.B. Mulder A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin J Thromb Haemost 8 2010 1193 1200
4. P. Bucciarelli, S.M. Passamonti, E. Biguzzi, F. Gianniello, F. Franchi, and P.M. Mannucci Low borderline plasma levels of antithrombin, protein C and protein S are risk factors for venous thromboembolism J Thromb Haemost 10 2012 1783 1791
5. J. Mateo, A. Oliver, M. Borrell, N. Sala, and J. Fontcuberta Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism-results of the Spanish Multicentric Study on Thrombophilia (EMET-Study) Thromb Haemost 77 1997 444 451
6. S.M. Boekholdt, and M.H. Kramer Arterial thrombosis and the role of thrombophilia Semin Thromb Hemost 33 2007 588 596
7. C. Orlando, O. Heylen, W. Lissens, and K. Jochmans Antithrombin Heparin Binding Site deficiency: a challenging diagnosis of a not so benign thrombophilia Thromb Res 135 2015 1179 1185
8. R.C. Tait, I.D. Walker, J.F. Davidson, S.I. Islam, and R. Mitchell Antithrombin III activity in healthy blood donors: age and sex related changes and prevalence of asymptomatic deficiency Br J Haematol 75 1990 141 142
9. S.R. Kristensen, B. Rasmussen, S. Pedersen, and L. Bathum Detecting antithrombin deficiency may be a difficult task-more than one test is necessary J Thromb Haemost 5 2007 617 618
10. G.W. Moore, N. de Jager, and J.A. Cutler Development of a novel, rapid assay for detection of heparin-binding defect antithrombin deficiencies: the heparin-antithrombin binding (HAB) ratio Thromb Res 135 2015 161 166
11. K. Javela, S. Engelbarth, L. Hiltunen, P. Mustonen, and M. Puurunen Great discrepancy in antithrombin activity measured using five commercially available functional assays Thromb Res 132 2013 132 137
12. M. Puurunen, P. Salo, S. Engelbarth, K. Javela, and M. Perola Type II antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population: clinical picture J Thromb Haemost 11 2013 1844 1849
13. J. Corral, D. Hernandez-Espinosa, J.M. Soria, R. Gonzalez-Conejero, A. Ordonez, and J.R. Gonzalez-Porras Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis Blood 109 2007 4258 4263
14. P.C. Cooper, F. Coath, M.E. Daly, and M. Makris The phenotypic and genetic assessment of antithrombin deficiency Int J Lab Hematol 33 2011 227 237
15. J.S. Ungerstedt, S. Schulman, N. Egberg, J. Antovic, and N. Blombäck Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: do factor Xa-based methods overestimate antithrombin activity in some patients? Blood 99 2002 2271 2272
16. D. Bruce, D.J. Perry, J.Y. Borg, R.W. Carrell, and M.R. Wardell Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn- > Asp) J Clin Invest 94 1994 2265 2274
17. N.J. Beauchamp, R.N. Pike, M. Daly, L. Butler, M. Makris, and T.R. Dafforn Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation Blood 92 1998 2696 2706
18. M.E. de la Morena-Barrio, T.S. Sevivas, I. Martinez-Martinez, A. Miñano, V. Vicente, and J. Jaeken Congenital disorder of glycosylation (PMM2-CDG) in a patient with antithrombin deficiency and severe thrombophilia J Thromb Haemost 10 2012 2625 2627
19. V. Roldán, A. Ordoñez, F. Marín, E. Zorio, J.M. Soria, and A. Miñano Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis Thromb Haemost 101 2009 483 486